Today: 11 June 2026
SoundHound AI stock jumps 7% as Wall Street resets targets after CES demos
10 January 2026
1 min read

SoundHound AI stock jumps 7% as Wall Street resets targets after CES demos

New York, January 10, 2026, 08:26 (EST) — Market closed

SoundHound AI, Inc. shares rose 6.7% to $11.75 at Friday’s close, after swinging between $11.15 and $12.31 in the session. About 39.3 million shares changed hands.

The move comes as investors sift through a burst of CES headlines and analyst reactions around “agentic” voice AI — systems meant to take actions, not just answer questions — in cars and on consumer devices. SoundHound this week pitched new voice-commerce features at CES and highlighted an automotive tie-up with TomTom.

DA Davidson cut its price target to $14 on Jan. 8 while keeping a Buy rating, after a CES event with SoundHound CEO Keyvan Mohajer and CFO Nitesh Sharan that included demos of the Amelia 7.3 platform, Investing.com reported. The brokerage said it had been too optimistic on near-term revenue growth as the company pushes into new revenue streams; StreetInsider attributed the move to DA Davidson analyst Gil Luria.

Oppenheimer analyst Brian Schwartz kept a Perform rating — broadly a market-like view — after the CES meeting and demos, calling SoundHound a “well run business,” according to Investing.com. The firm held the rating, citing valuation and what it called risks to sustaining profitable growth.

Cantor Fitzgerald reiterated an Overweight rating and a $15 price target after CES meetings, saying booth traffic ran about four times last year’s level based on management’s comments. Cantor said it turned “incrementally more positive” after hands-on demos and pointed to cross-selling and integration work with acquired customer bases.

On the charts, the stock ended Friday below its 50-day moving average of $12.04 and under its 200-day moving average of $13.48, reported. Traders will be watching whether it can reclaim the $12 area when Nasdaq reopens on Monday.

But the setup cuts both ways. If the company fails to convert CES interest into signed deals, or if margins lag while it scales new products, the stock can give ground quickly in a market that punishes expensive, unprofitable growth stories.

Next up is Tuesday’s U.S. consumer price index report for December, due at 8:30 a.m. ET, a release that often ripples through rate-sensitive tech shares. The next company catalyst is SoundHound’s quarterly results; the company has not confirmed a date, but MarketBeat’s calendar estimate points to Feb. 26.

Stock Market Today

  • Can T-Mobile Sustain Its Strong Customer Growth Momentum?
    June 11, 2026, 11:20 AM EDT. T-Mobile US reported a 6% year-over-year increase in postpaid net additions for Q1 2026, adding 217,000 accounts to reach 34.4 million, driven by network quality, value offerings, and 5G adoption. Postpaid Average Revenue Per Account (ARPA) rose 3.9% to $151.93, aided by rate plan optimization and business services. The company also boosted broadband subscribers by over 500,000, benefiting from fixed wireless speeds and fiber partnerships. T-Mobile raised its 2026 guidance for postpaid net additions to 950,000-1.05 million and expects ARPA growth of 2.5-3%. Competitors AT&T and Verizon continue aggressive expansion in fiber and 5G broadband, adding significant new customers, intensifying industry competition. Despite growth, T-Mobile's shares have fallen 19.6% over the past year and trade at a higher price/earnings ratio than the industry average.

Latest articles

S&P 500, Nasdaq, Dow edge higher as chip names catch a bid

S&P 500, Nasdaq, Dow edge higher as chip names catch a bid

11 June 2026
Oracle plunged 12.5% after projecting fiscal 2027 capital spending far above Wall Street estimates and planning to raise nearly $40 billion in debt and equity, dragging software stocks lower even as chipmakers fueled a partial tech rebound following Wednesday’s AI-led selloff, Reuters reported.
Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results
Previous Story

Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut
Next Story

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut

Go toTop